PMID- 12126538
OWN - NLM
STAT- MEDLINE
DCOM- 20020829
LR  - 20151119
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 82
IP  - 11
DP  - 2002 Jun 10
TI  - [The abnormal reaction to post methionine loading test in type diabetes with or 
      without retinopathy].
PG  - 725-8
AB  - OBJECTIVE: To investigate the reaction of patients with type 2 diabetes mellitus 
      (DM) with retinopathy (DR) or without retinopathy (NDC) to post methionine 
      loading (PML) test, the value of PML test to identify hyperhomocystenemia (Hhcy), 
      and the possible mechanism of vascular damages caused by Hcy. METHODS: Solution 
      of methione was given orally to 17DR patients, 15 NDC patients, and 28 normal 
      controls. The plasma fasting homocysteine (Fhcy) level and the Hcy levels 4 hours 
      after PML test (Phcy) of these subjects were measured by fluorescence 
      polarization immunoassay (FPIA) before and 4 hours after PML test. The levels of 
      fasting plasma folic acid and vitamin B(12) were tested by radioimmunoassay. 
      PCR-RFLP was used to test the mutation of methelene tetrahydrofolate reductase 
      (MTHFR) C6671. BMI, HbA1c, FBG, PBG, BUN, Cr, Ch and TG were also detected. The 
      final metabolites of NO were determined by Griess method. RESULTS: The levels of 
      BMI, HbA1c, FBG and PBG in DM group and NDC group were higher than those in the 
      control group (P < 0.05). The Fhcy levels were 13.87 micro mol/L and 11.6 +/- 1.3 
      micro mol/L in DR and NDC groups respectively, both higher than that in control 
      group (8.85 micro mol/L, both P < 0.05). The Phcy was 37.3 +/- 1.3 micro mol/L in 
      DR group and was 25.03 micro mol /L in NDC group, both higher than that in the 
      control group (22.65 micro mol/ L, both P < 0.05). The difference between Fhcy 
      and Phcy (Dhcy) was 24.36 micro mol/L in DR group and was 14.26 micro mol/L in 
      NDC group, both significantly higher than that in the control group (15.07 micro 
      mol/L, both P < 0.05). The proportion of BB genetype of MTHFR in DR group (9/17) 
      was higher than those in NDC group (5/28) and control group (2/15). The number of 
      Hhcy patients diagnosed by the level of Fhcy was 9 before PML test and became 15 
      after PML test diagnosed by the level of Phcy (P < 0.05). The whole prevalence of 
      Hhcy in DR group was higher than that in NDC group, both the prevalence of Hhcy 
      in DR group and the prevalence of Hhcy in NDC group were higher than those in CON 
      group (P < 0.001). The levels of fasting metabolite of NO were 5.4 +/- 1.8 micro 
      mol/L, 5.4 +/- 1.8 micro mol/L, and 3.4 +/- 1.7 micro mol/L in DR group, NDC 
      group, and control group respectively. The levels of metabolits of NO after meal 
      were 25.0 +/- 2.3 micro mol/L, 15.0 +/- 2.3 micro mol/L, and 10.4 +/- 2.0 micro 
      mol/L in DR group, NDC group, and control group respectively. The differences 
      between DR group and control group were statistically significant (P < 0.05). The 
      correlation coefficient of metabolites of NO to Hcy was 0.744 (P < 0.001). 
      CONCLUSION: Patients with diabetes mellitus, especially those with retinopathy, 
      had abnormal reaction to PML test, which may be related to higher BB genetype of 
      MTHFR and dysfunction of insulin. PML test can be used to identify more Hhcy 
      patients. Disturbance of NO metabolism may be one of the mechanisms of the 
      vascular damages caused by Hcy.
FAU - Guo, Qinghua
AU  - Guo Q
AD  - Department of Endocrinology, General Hospital of People's Liberation Army, 
      Beijing, China.
FAU - Lu, Juming
AU  - Lu J
FAU - Pan, Changyu
AU  - Pan C
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Nitrates)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - AE28F7PNPL (Methionine)
RN  - EC 1.5.- (Oxidoreductases Acting on CH-NH Group Donors)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*blood/complications/enzymology
MH  - Diabetic Retinopathy/*blood/etiology
MH  - Fasting
MH  - Female
MH  - Homocysteine/blood
MH  - Humans
MH  - Hyperhomocysteinemia/blood/complications/*diagnosis
MH  - Male
MH  - *Methionine/administration & dosage
MH  - Methylenetetrahydrofolate Reductase (NADPH2)
MH  - Middle Aged
MH  - Mutation
MH  - Nitrates/blood
MH  - Oxidoreductases Acting on CH-NH Group Donors/genetics
MH  - Time Factors
EDAT- 2002/07/20 10:00
MHDA- 2002/08/30 10:01
CRDT- 2002/07/20 10:00
PHST- 2002/07/20 10:00 [pubmed]
PHST- 2002/08/30 10:01 [medline]
PHST- 2002/07/20 10:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2002 Jun 10;82(11):725-8.